These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 36636835)

  • 1. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
    Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
    Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment.
    Semple JW; Schifferli A; Cooper N; Saad H; Mytych DT; Chea LS; Newland A
    Blood Rev; 2024 Sep; 67():101222. PubMed ID: 38942688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS; Zhukov OS; Sahud MA; Kuter DJ
    Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia.
    Walter O; Ribes A; Germain J; Rieu JB; Comont T; Plat A; Rivière B; Deluche L; Delarue L; LeGoff I; Greze M; Dubourdieu B; Rauzy O; Mansat-De Mas V; Moulis G;
    Platelets; 2022 Nov; 33(8):1153-1158. PubMed ID: 35348426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia.
    Pizzi M; Vianello F; Binotto G; Vianelli N; Carli G; Auteri G; Nichele I; Sbaraglia M; Zoletto S; Scarmozzino F; Bresciani R; d'Amore F; Friziero A; Guzzardo V; Bertozzi I; Famengo B; d'Amore ESG; Sabattini E; Dei Tos AP
    Br J Haematol; 2022 Sep; 198(5):916-922. PubMed ID: 35701886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi-structured interviews.
    Livingston J; Alrajhi Z; Jackson M; McGuire C; Newhook D; Klaassen RJ; Kirby-Allen M
    Br J Haematol; 2023 Feb; 200(4):506-516. PubMed ID: 36345812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.
    Garabet L; Ghanima W; Rangberg A; Teruel-Montoya R; Martinez C; Lozano ML; Nystrand CF; Bussel JB; Sandset PM; Jonassen CM
    Platelets; 2020; 31(2):198-205. PubMed ID: 30885035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
    Barlassina A; González-López TJ; Cooper N; Zaja F
    Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.